{"id":"NCT03632135","sponsor":"Cordgenics, LLC","briefTitle":"Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma","officialTitle":"Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-20","primaryCompletion":"2022-06-16","completion":"2023-12-31","firstPosted":"2018-08-15","resultsPosted":"2023-11-30","lastUpdate":"2025-04-15"},"enrollment":78,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Recurrent Glioblastoma"],"interventions":[{"type":"DIAGNOSTIC_TEST","name":"ChemoID assay","otherNames":[]},{"type":"DRUG","name":"Chemotherapy","otherNames":["Cytotoxic chemotherapy drugs"]}],"arms":[{"label":"Physician Choice treatment","type":"ACTIVE_COMPARATOR"},{"label":"ChemoID-guided treatment","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical study is to confirm the utility of chemosensitivity tumor testing on cancer stem cells (ChemoID) as a predictor of clinical response in poor prognosis malignant brain tumors such as recurrent glioblastoma (GBM).","primaryOutcome":{"measure":"Median Overall Survival (OS)","timeFrame":"36 months","effectByArm":[{"arm":"Physician Choice Treatment","deltaMin":7.5,"sd":null},{"arm":"ChemoID-guided Treatment","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["28199863","32197147","37287692","37137304"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":35},"commonTop":["Low white blood cells count","Platelet count decreased","Fatigue","Neuropathy","Constipation"]}}